H04
General Information
DRACP ID DRACP01525
Peptide Name H04
Sequence RNRVKLVNLXFATLREX
Sequence Length 17
UniProt ID Not available
PubChem CID Not available
Origin Synthetics
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
NCI-H524 | Lung small cell carcinoma; Small cell lung cancer | Carcinoma | EC50≈9 μM | MTT assay | Not available | Patent |
NCI-H526 | Lung small cell carcinoma; Small cell lung cancer | Carcinoma | EC50≈11 μM | MTT assay | Not available | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence
Chiral L
Physicochemical Information
Formula C81H137N27O19
Absent amino acids CDGHIMPQSWY
Common amino acids LR
Mass 229871
Pl 12.22
Basic residues 4
Acidic residues 1
Hydrophobic residues 7
Net charge 3
Boman Index -4534
Hydrophobicity -24.71
Aliphatic Index 108.82
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2021/0230226 A1
Patent Title Anticancer Peptides
Other Iinformation Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status: Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017
Other Published ID AU2018305923A1 CA3070874A1 CN111263768A EP3658576A1 JP2020528458A KR20200032183A WO2019020649A1